Abiopharma

🔍 Dachille Douglas A. (Director)

Company: BridgeBio Pharma, Inc. (BBIO)

Report Date: 2026-06-22

Detailed Transactions and Holdings:

• Acquired 3,990 shares of Common Stock (Direct)
  Date: 2026-06-22 | Code: A | equity_swap_involved: 0 | shares_owned_after: 10,579.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-22 | Code: H | nature_of_ownership: By The Dachille 2012-1 Family Trust | shares_owned_after: 20,000.00 | Footnotes: F3
• Acquired 5,277 shares of Stock Option (Right to Buy) at $68.92 per share (Derivative)
  Date: 2026-06-22 | Code: A | Expires: 2036-06-21 | equity_swap_involved: 0 | shares_owned_after: 5,277.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
• F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• F3: These shares are owned directly by The Dachille 2012-1 Family Trust for the benefit of the Reporting Person's children, for which the Reporting Person's spouse is the trustee. The Reporting Person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.
• F4: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
• REMARKS: Exhibit 24 - Power of Attorney